|Awarded On||September 14, 2022|
|Title||Novel Covalent Drugs for BCL6|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Walter Fast|
|Cancer Sites||Breast, Lymphoma|
*Pending contract negotiation
This application proposes to develop a new type of strategy for selectively killing cancerous cells in cases of breast cancer and diffuse large B-cell lymphoma. Breast cancer is the second most common cause of cancer death in Texas women, and diffuse large B-cell lymphoma is the most common type of lymphoma. Growth of each of these types of cancers can be stimulated by a specific protein called BCL6. Earlier tests have shown that when the function of this protein is blocked, cancerous cells can be killed but the surrounding normal cells are spared. Accordingly, there have been efforts from academic and industrial labs to make molecules that block BLC6, but these efforts have had shortcom...